Somewhat Positive Media Coverage Somewhat Unlikely to Impact Inovio Pharmaceuticals (INO) Stock Price

Media coverage about Inovio Pharmaceuticals (NASDAQ:INO) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.9538039637279 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

INO stock opened at $4.77 on Friday. The stock has a market capitalization of $461.06, a P/E ratio of -4.42 and a beta of 2.55. Inovio Pharmaceuticals has a 52-week low of $3.76 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.06. The business had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.13 million. Inovio Pharmaceuticals had a negative return on equity of 66.07% and a negative net margin of 208.92%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.35) earnings per share. research analysts expect that Inovio Pharmaceuticals will post -1.07 EPS for the current fiscal year.

A number of equities analysts have commented on the company. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada lifted their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, March 15th. Maxim Group set a $8.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. Finally, ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $19.07.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Inovio Pharmaceuticals (INO) Stock Price” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3294912/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-inovio-pharmaceuticals-ino-stock-price.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Astro 24-Hour Volume Reaches $3,638.00
Astro 24-Hour Volume Reaches $3,638.00
SyncFab Hits One Day Trading Volume of $45,979.00
SyncFab Hits One Day Trading Volume of $45,979.00
Microsoft Co.  Expected to Post Quarterly Sales of $25.71 Billion
Microsoft Co. Expected to Post Quarterly Sales of $25.71 Billion
Zacks: Analysts Anticipate Shutterstock  Will Announce Quarterly Sales of $150.17 Million
Zacks: Analysts Anticipate Shutterstock Will Announce Quarterly Sales of $150.17 Million
$8.32 Billion in Sales Expected for Enterprise Products  This Quarter
$8.32 Billion in Sales Expected for Enterprise Products This Quarter
Akamai Technologies  Expected to Post Quarterly Sales of $654.02 Million
Akamai Technologies Expected to Post Quarterly Sales of $654.02 Million


© 2006-2018 Ticker Report. Google+.